Category Archives: Gadolinium

Featured Stories

Medtronic Sprint Fidelis Leads Vulnerable to Fracture after ICD Switch

Medtronic Sprint Fidelis leads are vulnerable to fracture following ICD switch, says a new study published in the June issue of the journal Heart Rhythm.

Read More

FDA Gives 7 Companies Go Ahead To Market Generic Plavix

The U.S. Food & Drug Administration (FDA) just gave seven companies the go-ahead to market generic Plavix. Plavix is a blood thinner prescribed for the prevention of blood clots, heart attacks, and which has been linked to serious side effects such as the heart attacks and strokes it is supposed to ...

Read More

First Bard Avaulta Transvaginal Mesh Lawsuit Scheduled for February Trial in MDL

The first test trials in the federal C.R. Bard Avaulta transvaginal mesh litigation will most likely start next year, according to a report from Bloomberg News. About 600 lawsuits involving Bard Avaulta transvaginal mesh products are currently pending in the multidistrict litigation underway Charleston, West Virginia. U.S. District Judge Joseph ...

Read More

Study Linking Z-Pak to Increased Death Risk Being Reviewed by FDA

The U.S. Food & Drug Administration (FDA) is reviewing a new study that reported an increased risk of sudden, heart-related deaths among people using the antibiotic Zithromax (azithromycin), known popularly as Z-Pak. In a statement issued late yesterday, the FDA said patients being treated with Zithromax should not stop taking ...

Read More

FDA Advisors Set to Examine Metal-on-Metal Hip Implant Safety Concerns

Thousands of people with metal-on-metal hip implant devices could soon get some answers from the U.S. Food & Drug Administration (FDA) about the dangers they face. Tomorrow, the agency will convene a panel of outside medical experts to examine the safety record of metal-on-metal hip replacements, and recommend the ...

Read More

Birth Control Shot Depo-Provera may Increase HIV Risk

Birth Control Shot Depo-Provera may Increase HIV Risk, Study Suggests

A new study has linked the use of Depo-Provera (medroxyprogesterone acetate), an injectable type of birth control, to an increased risk of HIV infection.

Read More

Pradaxa Associated with more Complications than Warfarin, According to Early Study Findings

Early results from the largest study to date to compare Pradaxa and warfarin indicate that in a real-world setting, Pradaxa causes more complications than decades-old warfarin. The preliminary study results were announced last week, during the 2012 Thrombosis and Hemostasis Summit of North America.

Read More

Bayer Yaz, Yasmin Blood Clot Lawsuit Settlements Stand at $147 Million

Bayer AG reported yesterday that it continues to settle Yaz and Yasmin birth control pill lawsuits. According to a report from Bloomberg News, the company said in its latest Stockholder Newsletter that it has settled 651 Yaz and Yasmin blood clot lawsuits for a total of $147 million. The average ...

Read More

Transvaginal Mesh Lawsuit Trial

$5.5 Million Awarded to Plaintiffs in First Transvaginal Mesh Lawsuit Trial

An award of $5.5 million has been made in the first trial over a transvaginal mesh lawsuit. The jury found against medical device maker, C.R. Bard, and its Avaulta Plus transvaginal mesh. The jury agreed that Bard’s Avaulta Plus transvaginal mesh caused numerous and painful injuries in a California woman. ...

Read More

Government Penalizes 721 Hospitals for High Rates of Infections, Injuries

Medicare is reducing payments to 721 hospitals, one out of every seven hospitals in the nation, for having high rates of “hospital-acquired” conditions (HAC.

Read More

FDA Advisors Meet on Gadolinium Dyes; Find Omniscan, OptiMark and Magnevist are Most Dangerous

A panel of medical experts has found that several gadolinium contrast dyes – < "http://www.yourlawyer.com/articles/read/17387">OptiMark, Omniscan and Magnevist – appear to carry more risk of nephrogenic systemic fibrosis (NSF) than others currently on the market. The advisory panel met yesterday … Continue reading

Posted in Gadolinium, Pharmaceuticals |

Restrict Some Gadolinium Contrast Dyes, FDA Panel Says

The use of some gadolinium contrast dyes should be restricted because of their association with nephrogenic systemic fibrosis (NSF), according to a recommendation just made by a Food & Drug Administration (FDA) advisory panel. Reuters is reporting that the panel … Continue reading

Posted in Gadolinium, Pharmaceuticals |

Gadolinium Contrast Dyes Face FDA Advisory Panel Review Next Week

U.S. health regulators are set to review gadolinium contrast dyes this month. The Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee will meet on December 8 to review data … Continue reading

Posted in Gadolinium, Pharmaceuticals |

NSF Lawsuit Claims Hospital Negligent For Using Gadolinium Contrast Dyes

St. Luke’s Hospital in Chesterfield, Mo. faces a lawsuit filed by a victim of < "http://www.yourlawyer.com/topics/overview/nsf">nephrogenic systemic fibrosis (NSF). The plaintiff was administered a gadolinium based contrast dye at St. Luke’s several times starting in 2005, and was diagnosed with … Continue reading

Posted in Gadolinium, Pharmaceuticals |

Dialysis, Kidney Transplant Patients Face Higher Risk of NSF from Gadolinium Agents

A study of patients exposed to gadolinium contrast dyes at the Mayo Clinic has revealed that hemodialysis patients had a 77-fold higher risk of developing nephrogenic systemic fibrosis (NSF), while kidney transplant patients had a 69-fold higher risk of the … Continue reading

Posted in Gadolinium, Pharmaceuticals |

OptiMARK Gadolinium Contrast Agent Label Changed Over NSF Risk

The maker of OptiMARK gadolinium contrast agent is modifying the product’s label to contraindicate its use in patients with severe kidney impairment because of its association with nephrogenic systemic fibrosis (NSF). Mallinckrodt Inc., a Covidien company, has submitted this label … Continue reading

Posted in Gadolinium, Pharmaceuticals |

Magnevist, Omniscan and OptiMARK Have Highest Risk of NSF, FDA Says

Three gadolinium contrast dyes – Bayer Healthcare’s Magnevist, GE Healthcare’s Omniscan, and Covidien ‘s OptiMARK -carry a higher risk of < "http://www.yourlawyer.com/topics/overview/nsf">nephrogenic systemic fibrosis (NSF) than other agents on the market, according to the U.S. Food & Drug Administration (FDA). … Continue reading

Posted in Gadolinium, Pharmaceuticals |

FDA Decision to Treat Omniscan, Other Gadolinium Contrast Dyes Equally Questioned

A ProPublica investigation has found that a disproportionate number of Nephrogenic Systemic Fibrosis (NSF) cases have been associated with the use of General Electric’s (GE) < "http://www.yourlawyer.com/topics/overview/omniscan_gadolinium">Omniscan gadolinium contrast dye. Yet, according to the investigation, published in Business Week, the … Continue reading

Posted in Gadolinium, Pharmaceuticals |

Bayer Settles Some Magnevist Gadolinium Contrast Dye Lawsuits

Bayer AG has settled some lawsuits involving its < "http://www.yourlawyer.com/topics/overview/gadolinium">gadolinium contrast dye, Magnevist. Plaintiffs in the lawsuits claimed that Magnevist had caused Nephrogenic Systemic Fibrosis (NSF), a potentially fatal condition that develops in people with pre-existing kidney disease. Gadolinium contrast … Continue reading

Posted in Gadolinium |

Study Suggests "Potent" Link Between NSF, Gadolinium Contrast Dyes

Another study has found a strong link between the use of gadolinium contrast dyes and the development of Nephrogenic Systemic Fibrosis (NSF). According to researchers at the University of Pennsylvania in Philadelphia, patients with advanced chronic kidney disease were 27 … Continue reading

Posted in Gadolinium |

© 2005-2018 Parker Waichman LLP ®. All Rights Reserved.